Novartis says positive interim results on rare kidney disease drug

by

Swiss pharmaceutical giant Novartis on Monday reported positive interim Phase III results for a new drug being studied to treat a rare kidney disease.

Leave A Comment

Your email address will not be published. Required fields are marked *